Treatment of brain metastases in ALK-positive non-small cell lung cancer.
ALK-translocation
Alectinib
Brain metastases
Brigatinib
Crizotinib
Lorlatinib
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
05
02
2021
revised:
31
05
2021
accepted:
03
06
2021
pubmed:
21
6
2021
medline:
15
9
2021
entrez:
20
6
2021
Statut:
ppublish
Résumé
Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC): they are often not amenable to surgical resection and are generally treated with radiotherapy (RT). This however causes severe late toxic side effects that may become invalidating considering the relatively long survival provided by recent medical treatment with target therapies. Several clinical trials have demonstrated that ALK-inhibitors (crizotinib, alectinib, brigatinib) show excellent activity also against brain metastases. It is therefore reasonable, in asymptomatic patients, to start treatment with specific inhibitors: RT will be used at the time of tumor progression or when symptoms appear. This sequence provides the best quality of life for patients.
Identifiants
pubmed: 34147645
pii: S1040-8428(21)00188-8
doi: 10.1016/j.critrevonc.2021.103400
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103400Informations de copyright
Copyright © 2021. Published by Elsevier B.V.